Currently, the most common medication for CPP is leuprorelin, which is a gonadotropin-releasing hormone (GnRH) analog, and the use of leuprorelin for suppressing puberty patients with CPP caused by MKRN3 mutations has been reported. The gene discussed is GNRH1; the disease is central precocious puberty.